Boron One Announces Update to Early Warrant Exercise Incentive Program

VICTORIA, BC / / April 22, 2025 / Boron One Holdings Inc. ("Boron One" or the "Company") (TSXV:BONE), is providing an update to its press release dated April 7, 2025 announcing the warrant exercise incentive program. The Program is intended to encourage the exercise of up to 9,691,000 unlisted common share purchase warrants of the Company (the "Eligible Warrants") which were issued as part of the Company's private placements which closed on June 7, 2024, September 10, 2024 and September 25, 2024, respectively. Each Eligible Warrant is exercisable for one common share of the Company (each a "Common Share") at a price of $0.07 per Common Share. The Company intends to amend the exercise price to $0.05 (the "Warrant Repricing") for the term of the Warrant Incentive Program, following receipt of TSX Venture Exchange (the "Exchange") acceptance. All other terms of the Eligible Warrants will remain the same, including the expiry dates of December 7, 2026 for the June 7, 2024 Warrants, March 10, 2027 for the September 10, 2024 Warrants and March 25, 2027 for the September 25, 2024 Warrants. Upon the expiration of the Warrant Incentive Program, the exercise price of any unexercised Eligible Warrants will revert to the original exercise price of $0.07 per Common Share.
To the extent that holders of Eligible Warrants ("Warrant Holders") take advantage of the opportunity to exercise their Eligible Warrants early, this will fund working capital purposes. Eligible Warrants that remain unexercised following the completion of the Early Exercise Period (defined below) will continue to be exercisable for Common Shares on the original terms as they existed prior to the Program.
The Early Exercise Period will commence on April 23, 2025 and terminate on May 7, 2025.
The Program and Warrant Repricing are subject to approval from the Exchange and the receipt of all final regulatory approvals, including final approval of the Exchange. Insiders presently hold 900,000 Eligible Warrants. The number of Eligible Warrants to be exercised by insiders of the Company is limited to no more than 10% of the total Eligible Warrants, being 969,100 Eligible Warrants, and the Company will issue no more than 969,100 Incentive Warrants to insiders under the Program.
On behalf of the Board of Directors,Tim Daniels, President
About Boron One Holdings Inc.Boron One Holdings Inc. is an international mineral exploration and development company with boron assets in Serbia. Headquartered in Victoria, B.C., Canada, Boron One's shares are traded on the Exchange under the symbol "BONE". For detailed information please see Boron One's website at www.boronone.com or the Company's filed documents at www.sedarplus.ca
For further information, please contact:
Boron One Holdings Inc.
Blake Fallis, General Manager
Phone: 1-250- 384-1999 or 1-888-289-3746
info@boronone.com
www.boronone.com
Boron's Public Quotations:CanadaTSX Venture:BONEBerlin:EKVUS: SEC 12G3-2(B) #82-4432ERVFFOTC PINK:ERVFF
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Boron One Holdings Inc.
View the original press release on ACCESS Newswire

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

Magma Silver Announces Marketing Agreement

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2025) - Magma Silver Corp. (TSXV: MGMA) (OTCQB: MAGMF) (FSE: BC21) (WKN: A411DV) (the "Company" or "Magma") is pleased to announce that it has retained the services of Vancouver-based Matrix Agency Marketing Ltd. ("Matrix"), a marketing and consulting services company focused on the junior mining sector. Under the terms of the engagement agreement (the "Agreement"), the Company will compensate Matrix $7,000 per month, over a 12-month initial term of the Agreement. No stock options of shares of Magma are included in the terms of this Agreement. Matrix may be awarded stock options at some time in the future at the full discretion of the Board of Directors of Magma. Matrix and or its affiliates currently hold no Magma shares but may from time to time acquire or dispose of securities of the Company through the market, privately or otherwise, as circumstances or market conditions warrant. Matrix is at arm's length to Magma Silver Corp. and has no other relationship with the Company, except pursuant to the Agreement." The Agreement has been conditionally approved by the TSX Venture Exchange. The Company is pleased to welcome the addition of Matrix to its investor relations team, for the purpose of providing certain market and investor relations services in accordance with the policies of the TSX Venture Exchange (the "Exchange"). By leveraging Matrix, the Company hopes to heighten market awareness for Magma and its business, including the Company's exploration and development plans for its flagship Niñobamba silver-gold project in Southeast Peru. Matrix is a marketing firm based out of Vancouver, British Columbia specializing in the junior mining sector with expertise in marketing strategy, graphic and web design, communications and content marketing, including PR and event coordination. About Magma Silver Corp. Magma Silver Corp. is a natural resource company with a focus on the acquisition, exploration, development, and operation of precious metal mining exploration projects. The Company's primary focus is on exploring and developing the advanced Niñobamba silver gold project in the mining supportive country of Peru. For further information, please contact Magma Silver Corp.: Jason Baker, Chief Financial OfficerPhone: +1-604-252-2672Email: info@ Reader Advisory This news release may contain forward-looking information within the meaning of applicable securities laws. All information and statements other than statements of current or historical facts contained in this news release are forward-looking information. Forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Magma Silver Corp.'s periodic filings with Canadian securities regulators. When used in this news release, words such as "will", "could", "plan", "estimate", "expect", "intend", "may", "potential", "should," and similar expressions, are forward- looking statements. The information provided in this document is necessarily summarized and may not contain all available material information. Forward-looking statements include those in relation to (i) the Agreement and the performance thereof, (ii) the expected benefits to the Company from the Agreement and the scope of services to be provided by Matrix and (iii) the potential of the Niñobamba project. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can't make any assurances that its expectations will be achieved. Such assumptions may prove incorrect. Although the Company has attempted to identify important factors that could cause actual results, performance, or achievements to differ materially from those contained in the forward- looking statements, there can be other factors that cause results, performance, or achievements not to be as anticipated, estimated, or intended. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances, or results will materialize. As a result of these risks and uncertainties, no assurance can be given that any events anticipated by the forward-looking information in this news release will transpire or occur, or, if any of them do so, what benefits that the Company will derive therefrom. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this news release, and the Company disclaims any intention or obligation to update or revise such information, except as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Business Wire

an hour ago

• Business Wire

Deadline Alert: Vestis Corporation (VSTS) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP reminds investors of the upcoming deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Vestis Corporation ('Vestis' or the 'Company') (NYSE: VSTS) securities between May 2, 2024, to May 6, 2025, inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR VESTIS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On May 7, 2025, Vestis released its second quarter fiscal 2025 financial results and revised its prior growth and revenue guidance for 2025, providing guidance for the third quarter, falling significantly below market expectations. The Company explained that the poor results were partially due to 'lost business in excess of new business' but primarily on 'lower adds over stops, which is how [it] describe[s] volumes changes with [its] existing customers.' On this news, Vestis's stock price fell $3.27, or 37.5%, to close at $5.44 per share on May 7, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company was not equipped to achieve its growth guidance as the realization of these efforts instead resulted in a significant decline of revenue from existing customers; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Vestis securities during the Class Period, you may move the Court no later than August 8, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Business Wire

2 hours ago

• Business Wire

In a Context of Critical Financial Situation, CARMAT Launches a Donation Campaign Open to All to Contribute to Its Funding and Continuation of Its Activities

PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the launch of a donation campaign open to all, to help fund its operations and continue its mission. Critical financial situation and risk of insolvency at the end of June 2025 In a separate press release published today (see the press release), CARMAT announced that it is currently in a critical financial situation and facing a risk of insolvency as early as the end of June 2025. The Company estimates its 12-month financial needs at approximately €35 million, including €3.5 million needed urgently before the end of June 2025, and an additional €4.5 million by the end of July 2025. Despite efforts that are still ongoing, the Company has not yet been able to secure the financing required to continue its operations. Launch of a donation campaign Against this backdrop, and while continuing its efforts to raise funds, particularly through potential capital increases, CARMAT is today launching a donation campaign open to all. This initiative aims to allow individuals and organizations who support CARMAT's mission and wish to contribute to the continuity of its operations to do so. Practical information on the donation campaign The campaign opens on Friday, June 20, 2025. Donations can only be made via the platform (available on this link). Should they experience issues, donors are invited to contact CARMAT at the following email address: donor@ Main risks associated with donations Potential donors' attention is drawn to the fact that donations made as part of this campaign are non-refundable and do not entail any equity stake in the Company. Donors will therefore not become creditors or shareholders of CARMAT through their donation. Donors should also be aware that there is no guarantee that the donations received as part as this campaign, even in combination with any potential capital increases or other financing solutions that the Company could secure, will be sufficient to prevent a default at the end of June 2025 or beyond. As such, a default of the Company remains possible, even in the very short term. Furthermore, donations made in the context of this campaign do not entitle donors to any tax benefits of any kind. CARMAT, one of the most innovative French medtech companies in the world A technological breakthrough: Aeson ®, the world's first physiological artificial heart, to be both pulsatile, self-regulated, and highly hemocompatible Increasing adoption by the medical community: over 120 patients treated worldwide, including more than 70 over the past 18 months Recognition by experts worldwide: more than 60 hospitals trained across 17 countries A team of around 180 highly skilled and committed people Stéphane Piat, Chief Executive Officer of CARMAT, concludes: ' After 30 years of research and with 120 patients treated, CARMAT's artificial heart is now the most advanced artificial heart in the world and the most credible solution to address the major challenge of advanced heart failure. This condition is currently the world's leading cause of death. As of today, heart transplantation remains the gold standard treatment, but human donor hearts are unfortunately not available in sufficient numbers, leaving thousands of patients without any solution every year. CARMAT's heart is therefore absolutely essential to fight this growing health crisis and bring hope to patients and their families. In order to continue its mission, CARMAT urgently needs €3.5 million by the end of June 2025, and approximately €35 million over the next 12 months. Failing that, we will most likely be forced to cease operations. Despite our best efforts in a highly deteriorated environment, we have not yet been able to secure the financing required to continue our mission. This is why we are today calling on everyone's generosity to help CARMAT continue saving lives.' About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway extends only until the end of June 2025, and that CARMAT is therefore facing a very high risk of default, including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson ® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson ® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson ® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson ®. In the United States, Aeson ® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).